Rejuvenate Bio
Gene therapy company built out of George Church’s lab at Harvard Medical School. Its non-genome-editing platform is designed to give the body long-term production of therapeutic proteins from a single administration rather than ongoing medication.
INDUSTRY
Gene Therapy, Longevity Science
SECTOR
Biotech / Gene Therapy / Chronic Disease
FOCUS
Cardiovascular Disease, Metabolic Disorders, Animal Health
TECHNOLOGY
Non-Genome-Editing Gene Therapy Platform
STAGE OF INVESTMENT
Series B
HEADQUARTERS
San Diego, CA
WEBSITE
Rejuvenate Bio is rethinking what chronic treatment could look like. Instead of asking patients to manage disease every day, its platform is designed to deliver durable therapeutic benefit from a single administration.
Chris Yoo, PhD
Fund Manager
What they do.
Rejuvenate Bio is developing gene therapies designed to address chronic and age-related diseases with long-lasting treatment from a single administration. Its platform uses liver-directed gene therapy to enable the body to continuously produce therapeutic proteins, with programs spanning cardiovascular disease, metabolic disorders, and animal health.
Why we invested.
Rejuvenate combines the scientific foundation of George Church’s lab with a platform targeting some of healthcare’s largest chronic-disease markets. What stood out was its ability to validate the technology through animal-health programs while its human pipeline advances, including a strategic R&D partnership with Merck Animal Health. That creates a path to build clinical evidence and commercial value while pursuing the larger opportunity in human health.
Leadership
George Church, Ph.D.
Co-Founder and SAB
Daniel Oliver, MBA
CEO, Co-Founder
Noah Davidsohn, Ph.D.
CSO, Co-Founder
Deborah Ascheim, M.D.
Chief Medical Officer
